14989 results for "cancer studies using rna-seq"

in 15.40 milliseconds.

• Cancer Genome Libraries Tests

  Cancer Genome Libraries Tests

  Dataset EGAD00001000094

• Triple Negative Breast Cancer Whole Genomes

  Triple Negative Breast Cancer Whole Genomes

  Dataset EGAD00001000141

• SNP array datas of Matched cancer-PNE

  SNP array datas of Matched cancer-PNE

  Dataset EGAD00010001631

• The genomic landscape of large and small tumors in early-onset prostate cancer patients

  Study EGAS00001000383

• Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients

  Study EGAS00001004975

• WGS of oesophagogastric cancer

  Illumina short read WGS of 12 oesophagogastric cancer samples

  Dataset EGAD50000002239

• Study on rectal mucus sampling for colorectal cancer diagnostics

  DAC for a study on rectal mucus sampling for colorectal cancer diagnostics

  Dac EGAC50000000643

• Long-read WGS of three cancer cell lines

  Long-read WGS of three cancer cell lines

  Dataset EGAD00001005184

• Exome sequencing of high-risk prostate cancer

  Exome sequencing of high-risk prostate cancer

  Dataset EGAD00001002009

• SNP data for Ovarian cancer PRS

  SNP data for Ovarian cancer PRS (cases)

  Dataset EGAD00001008143

• Effects of interferon-gamma treatment on human small intestinal organoids generated from healthy donors

  The intestine is vulnerable to interferon-gamma as intestinal epithelial stem cells undergo cell death when exposed to interferon-gamma. Here, we developed a novel human intestinal organoid-based 3D model system to study the effects of interferon-gamma-induced intestinal epithelial damage at the RNA level. We treated organoids with 10 ng/mL for either 6 or 18h. Knowledge generated with this dataset is relevant for a variaty of intestinal pathologies with an immune component, for instance graft-versus-host disease.

  Study EGAS50000000083

• Immune Profiling in Patients with High-Risk Smoldering Myeloma

  Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Multiple Myeloma (SMM). We conducted a Phase II trial of the immunotherapeutic anti-SLAMF7 antibody, Elotuzumab, in combination with Lenalidomide and Dexamethasone (E-PRISM study), to determine the utility and safety of early immunotherapy in patients with high-risk SMM and develop biomarkers for optimal patient selection and monitoring of response to treatment.There is an overlap in subjects between this study and dbGaP accession phs001323.

  Study phs002476

• NHLBI TOPMed: Children's Health Study (CHS) Integrative Genomics and Environmental Research of Asthma (IGERA)

  The Integrative Genomics and Environmental Research of Asthma (IGERA) Study was proposed to collect immortalized cell lines, RNA, cDNA and DNA from 400 well-characterized subjects who participated in the southern California Children's Health Study (CHS) and to develop an accompanying database for these samples consisting of extensive phenotype, exposure, genome-wide genotype, gene expression, and methylation data. A subset of Hispanic-White participants (n=160) were included in the TOPMed project, including 77 asthma cases and 83 controls.

  Study phs001603

• Metatranscriptomic Sequencing of Pre-Transplant Bronchoalveolar Lavage in Pediatric Stem Cell Transplant Patients

  Children with malignancies, immunodeficiencies, and other life-threatening diseases sometimes receive allogeneic hematopoietic cell transplantation (HCT) as a treatment for their disease. The HCT process can be complicated by the development of lung disease from infection, alloreactivity, or other causes. To identify patients at-risk for post-HCT lung disease, this study uses metatranscriptomic RNA sequencing of bronchoalveolar lavage (BAL) obtained prior to HCT. Sequencing results are associated with the development of post-HCT lung injury. 

  Study phs002208